Cílené terapie při léčbě pokročilého nemalobuněčného karcinomu plic: nové poznatky

English version

Autoři: L. Mendoza
Působiště autorů: INC Research, Prague, Czech Republic
Vyšlo v časopise: Klin Onkol 2009; 22(4): 131-138
Kategorie: Přehledy

Souhrn

Po několika letech klinických studií pokročilého nemalobuněčného karcinomu plic (non small cell lung cancer – NSCLC), které byly charakteristické nedostatečnou účinností chemoterapie v porovnání s nejlepší podpůrnou péčí, jsme v poslední době zaznamenali významný klinický přínos vybraných cílených terapií. Během neustálého vývoje těchto nových protinádorových terapií byla prokázána lepší prognóza přežití nejen v prvotní léčbě, ale v poslední době dokonce u pacientů s recidivou po předchozí jedné nebo dvou neúspěšných chemoterapiích. Prvními látkami v této rozsáhlé skupině, u kterých byla prokázána klinická účinnost, byly tyrozinkinázové (TK) inhibitory receptorů epidermálního růstového faktoru (epidermal growth factor receptor – EGFR). Nejlepšími zástupci nových léčiv pro kontrolu a zmírnění nádoru jsou erlotinib (typ EGFR) a bevacizumab (receptor vaskulárního endotelového růstového faktoru – vascular endothelial growth factor receptor – VEGFR). Tento článek uvádí přehled nejslibnějších nově cílených látek včetně těch, které již byly schváleny a v současné době jsou v lékařské praxi používány.

Klíčová slova:
nemalobuněčný karcinom plic – tyrozin kináza – EGFR – VEGFR

Zdroje

1. Rapp E, Pater JL, Willan A et al. Chemotheraphy can prolong survival in patients with advanced non smalll-cell lung cancer – report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633–641.

2. Breathnach OS, Freidlin B, Conley B et al. Twenty-two years of phase II trials for patients with advanced non small cell lung cancer: sobering results. J Clin Oncol 2001; 19: 1734–1742.

3. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl 4): 9–15.

4. Ohsaki Y, TANNO S, Fujita Y et al. Epidermal growth factor receptor expression correlates with poor prognosis in non small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7: 603–607.

5. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non small cell lung carcinomas: correlation between gene copy number and protein expression and impact in prognosis. J Clin Oncol 2003; 21(20): 3798–3807.

6. Onn A, Choe DH, Herbst RS et al. Tumor cavitation in stage I non small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 2005; 237(1): 342–347.

7. Dacic S, Flanagan M, Cieply K et al. Significancer of EGFR protein expression and gene amplification in non small cell lung carcinoma. Am J Clin Pathol 2006; 125(6): 860–865.

8. Wislez M, Antoine M, Poulot V et al. IFCT0401-bio trial: predictive biological markers for disease control of patients with non resectable, adenocarcinoma with bronchioloalveolar features treated with gefitinib. Proc Am Soc Clin Oncol 2007; 25: 18. Abstract 7653.

9. Nakamura H, Kawasaki N, Taguchi M et al. Survival impact ofeppidermal growth factor receptor overexpression in patients with non small cell lung cancer: a meta analysis. Thorax 2006; 61(2): 140–145.

10. Dassonville O, Bozec A, Fischell JL et al. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors: similarities and differences. Crit Rev Oncol Hematol 2007; 62(1): 53–61.

11. Fukuoka M, Yano S, Giaccone G et al. Multi institutional randomized phase II trial of gefitinib for previously treated patients with advanced no-small cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237–2246.

12. Kris MG, Natale RB, Hebst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor TK, in symptomatic patients with non small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149–2158.

13. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non small cell lung cancer: a phase II trial – INTACT 1. J Clin Oncol 2004; 22: 777–784.

14. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non small cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004; 22: 785–794.

15. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: results from a randomized, placebo-controlled, multicenter study (Iressa Survical Evaluation in Lung Cancer). Lancet 2005; 366: 1527–1537.

16. AstraZeneca. Gefitinib (IressaTM) marketing authorisation application withdrawn in EU. January 4, 2005. Available from: http://www.astrazeneca.com/pressrelease/4442.aspx.

17. National Cancer Institute. Clinical Trial of Gefitinib for Advanced Lung Cancer Closes Early. April 18, 2005. Available from: http://www.nci.nih.gov/newscenter/pressreleases/gefitinibNSCLC.

18. Cufer T, Vrdoljak E, Gaafar R et al. Phase II, open-label, randomized study (SIGN) of single agent gefitinib (IRESSA) or docetaxel as second line therapy in patients with advanced (stage IIIb or IV) non small cell lung cancer. Anticancer Drugs 2006; 17(4): 401–409.

19. Perez-Soler R, Chachoua A, Hammond LA et al. Determinats of tumor response and survival with erlotinib in patients with non small cell lung cancer. J Clin Oncol 2004; 22(16): 3238–3247.

20. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12 (20 Pt 1): 6049–6055.

21. Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotheraphy-naïve patients > or = 70 years of age treated with erlotinib for advanced non small cell lung cancer. J Clin Oncol 2007; 25(7): 760–766.

22. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a phase III trial of erlotinib (OSI–774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(12): 1545–1552.

23. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phae III trial of erlotinib hydrocloride (OSI–774) combined with carboplatin and paclitaxel CT in advanced non small cell lung cancer. J Clin Oncol 2005; 23(25): 5892–5899.

24. Shepherd FA, Rodrigues Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non small cell-lung cancer. N Engl J Med 2005; 353: 123–132.

25. Janne PA, Gurubhagavatula S, Yeap BY et al. Outcomes of patients with advanced non small cell lung cancer treated with gefitinib (D1839, “Iressa”) on an expanded access study. Lung Cancer 2004; 44(2): 221–230.

26. Lee DH, Han JY, Yu SY et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol 2006; 1(9): 965–971.

27. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005; 353(2): 133–144.

28. Lu JF, Eppler SM, Wolf J et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure safety relationship in patients with non small cell lung cancer. Clin Pharmacol Ther 2006; 80(2): 136–145.

29. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controled study in advanced non small cell lung cancer. Clin Oncol 2006; 24(1): 5034–5042.

30. Laack E, Schneider C, Gutjahr T et al. Association between different potential predictive markers from TRUST, a trial of erlotinib in non small cell lung cancer. J Proc Am Soc Clin Oncol 2007; 25: 18. Abstract 7651.

31. Bell DW, Lynch TJ, Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non small cell lung cancer molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23(11): 8081–8092.

32. Yang SH, Mechanic LE, Yang P et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non small cell lung cancer. Clin Cancer Res 2005; 11(6): 2106–2110.

33. Murray S, Timotheadou E, Linardou H et al. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non small cell lung cancer patients. Lung Cancer 2006; 52(2): 225–233.

34. Niho S, Kubota K, Goto K et al. First line single agent treatment with gefitinib in patients with advanced non small cell lung canecr: a phase II study. J Clin Oncol 2006; 24(1): 1599–1603.

35. Ohtsuka K, Ohnishi H, Furuyashiki G et al. Clinico-pathological and biological significancer of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma. J Thorac Oncol 2006; 1(8): 787–795.

36. Wu YL, Zhong WZ, Li LY et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non small cell lung cancer: a meta analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007; 2(5): 430–439.

37. Kashii T, Okamoto I, Urata Y et al. EGFR mutation based phase II multicenter trial of gefitinib in advanced non small cell lung cancer patients: results of West Japan Thoracic Oncology Group Trial (WJTOG0403). 31st ESMO Congress 2006. Abstract 717.

38. Porta R, Terrasa J, Rolfo C et al. Deciding on second- or third line erlotinib in stage IV non small cell lung cancer patients based on the presence of mutations in the TK domain of the epidermal growth factor receptor. 31st ESMO Congress 2006. Abstract 719.

39. Massuti B, Reguart N, Vivanco GL et al. First line erlotinib in stage IV non small cell lung cancer patients with mutations in the TK domain of the epidermal growth factor receptor. 31st ESMO Congress 2006. Abstract 720.

40. Cappuzzo F, Hirsh FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non small cell lung cancer. J Natl Cancer Inst 2005; 97: 643–655.

41. Lynch TJ, Lilenbaum R, Bonomi P et al. A phase II trial of cetuximab as therapy for recurrent non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: 634. Abstract 7084.

42. Rosell R, Robinet G, Szczesna A et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first line therapy in EGFR-expressing advanced non small cell lung cancer. Ann Oncol 2008; 19(2): 362–369.

43. Pirker R, Szczesna A, Von Pawel J et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first line treatment of patients with advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008; 26. Abstract 3.

44. Crawford J, Sandler AB, Hammond LA et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: 634. Abstract 7083.

45. Cappuzzo F, Varella-Garcia M, Shigematsu H et al. Increased HER2 gene copy number associated with response to gefitinib therapy in epidermal growth factor receptor-positive non small cell lung cancer patients. J Clin Oncol 2005; 23(22): 5007–5018.

46. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non small cell lung cancer. Clin Cancer Res 2006; 12 (14 Pt 2): 4377–4383.

47. Langer CJ, Stephenson P, Thor A et al. Trastuzumab in the treatment of advanced non small cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 2004; 22(7): 1180–1187.

48. Herbst RS, Davies AM, Natale RB et al. Efficacy and safety of single agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007; 13(20): 6175–6181.

49. Herbst RS, Hidalgo M, Pierson AS et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol 2002; 29 (Suppl 4): 66–77.

50. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non small cell lung cancer. J Clin Oncol 2004; 22: 2184–2191.

51. Sandler AB, Gray R, Perry M et al. Paclitaxel-Carboplatin Alone or with bevacizumab for non small cell lung cancer. N Engl J Med 2006; 355: 2542–2550.

52. Manegold C, Von Pawel J, Zatloukal P et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non squamous non small cell lung cancer (NSCLC): BO17704. Proc Am Soc Clin Oncol 2007; 25: 18. Abstract LBA 7514.

53. Laurie SA, Gauthier I, Arnold A et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non small cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008; 26(11): 1871–1878.

54. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645–4655.

55. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a VEGF receptor TK inhibitor, in human cancer cells with acquired resistance o antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784–793.

56. Taguchi F, Koh Y, Koizumi F et al. Anticancer effects of ZD6474, a VEGF receptor TK inhibitor, in gefitinib (Iressa)-sensitive and resistant xenograft models. Cancer Sci 2004; 95: 984–989.

57. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic nd therapeutic implications. J Clin Oncol 2005; 23(14): 3243–3256.

58. Johnson BE, Ma P, West H et al. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st line treatment in patients with NSCLC. Proc Am Soc Clin Oncol 2005; 23: 16. Abstract 7102.

59. Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small cell lung cancer. J Clin Oncol 2007; 25(27): 4270–4277.

60. Natale RB, Bodkin D, Govindan R et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two part, double-blind, randomized phase II trial. Proc Am Soc Clin Oncol 2006; 24: 18. Abstract 7000.

61. Wilhelm SM, Carter C, Tang LY et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and target the RAF/MEK/ERK pathway and receptor TKs involved in tumor progression and angiogenesis. Cancer Res 2005; 64: 7099–7109.

62. Adams J, Huang P, Patrick D. A strategy for the design of multiple inhibitors for kinase-medited signalling in agiogenesis. Curr Opin Chem Biol 2002; 6: 486–492.

63. Carter CA, Chen C, Brink C et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non small cell lung carcinoma. Cancer Chemother Pharmacol 2007; 59(2): 183–195.

64. Liu B, Barett T, Choyke P et al. A phase II study BAY 43–9006 (Sorafenib) in patients with relapsed non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2006; 24: 18. Abstract 17119.

65. Gatzemeier U, Blumenschein G, Fosella F et al. Phase II trial of single agent sorafenib in patients with advanced non small cell lung carcinoma. Proc Am Soc Clin Oncol 2006; 24: 18. Abstract 7002.

66. O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 TK inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597–3605.

67. Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non small cell lung cancer. J Clin Oncol 2008; 26(4): 650–656.

68. Brahmer JR, Govindan S, Novello R et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non small cell lung cancer (NSCLC): Results from a phase II study. Proc Am Soc Clin Oncol 2007; 25: 18. Abstract 7542.